MAPT and Alzheimer disease: In vivo, CLR01 was evaluated in the triple-transgenic (3 × Tg) mouse model of AD, which overexpresses mutant forms of human presenilin 1 (PS1), amyloid β-protein precursor (APP), and tau [23].